Abstract
Obesity is associated with a wide range of complications, including type 2 diabetes mellitus, cardiovascular disease, hypertension and nonalcoholic fatty liver disease. Obesity also increases the incidence and progression of cancers, autoimmunity and infections, as well as lowering vaccine responsiveness. A unifying concept across these differing diseases is dysregulated immunity, particularly inflammation, in response to metabolic overload. Herein, we review emerging mechanisms by which obesity drives inflammation and autoimmunity, as well as impairing tumour immunosurveillance and the response to infections. Among these mechanisms are obesity-associated changes in the hormones that regulate immune cell metabolism and function and drive inflammation. The cargo of extracellular vesicles derived from adipose tissue, which controls cytokine secretion from immune cells, is also dysregulated in obesity, in addition to impairments in fatty acid metabolism related to inflammation. Furthermore, an imbalance exists in obesity in the biosynthesis and levels of polyunsaturated fatty acid-derived oxylipins, which control a range of outcomes related to inflammation, such as immune cell chemotaxis and cytokine production. Finally, there is a need to investigate how obesity influences immunity using innovative model systems that account for the heterogeneous nature of obesity in the human population.
Key points
-
Obesity dysregulates immunity through differing mechanisms, which contribute to a range of secondary complications.
-
Obesity influences the level and function of nutritionally regulated hormones that regulate signalling pathways that mediate immune cell metabolism and function and drive inflammation.
-
Expansion of adipose tissue dysregulates the abundance and composition of extracellular vesicles, which carry a wide range of cargo that can affect the activity of immune cells and lipid metabolism.
-
Increased adiposity dysregulates polyunsaturated fatty acid metabolism; notably, the concentration of oxylipins synthesized from polyunsaturated fatty acids, which control a range of outcomes related to inflammation, is imbalanced in obesity.
-
Investigating immunity in obesity requires translation from inbred rodents to humans; one approach is to use Diverse Outbred and Collaborative Cross mouse populations that can model the heterogeneous nature of human obesity.
Similar content being viewed by others
References
Ogden, C. L., Carroll, M. D., Kit, B. K. & Flegal, K. M. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 311, 806–814 (2014).
Gordon-Larsen, P. & Heymsfield, S. B. Obesity as a disease, not a behavior. Circulation 137, 1543–1545 (2018).
Lee, A., Cardel, M. & Donahoo, W. T. Social and environmental factors influencing obesity (eds Feingold, K. R. et al.) Endotext [Internet] https://www.ncbi.nlm.nih.gov/books/NBK278977/ (MDText.com, 2019).
Gordon-Larsen, P. et al. Synergizing mouse and human studies to understand the heterogeneity of obesity. Adv. Nutr. 12, 2023–2034 (2021).
Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 127, 1–4 (2017).
Popkin, B. M. et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes. Rev. 21, e13128 (2020).
Petrilli, C. M. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 369, m1966 (2020).
Lighter, J. et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin. Infect. Dis. 71, 896–897 (2020).
Kalligeros, M. et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity 28, 1200–1204 (2020).
Simonnet, A. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 28, 1195–1199 (2020).
Czernichow, S. et al. Obesity doubles mortality in patients hospitalized for severe acute respiratory syndrome coronavirus 2 in Paris hospitals, france: a cohort study on 5,795 patients. Obesity 28, 2282–2289 (2020).
Green, W. D. & Beck, M. A. Obesity impairs the adaptive immune response to influenza virus. Ann. Am. Thorac. Soc. 14, S406–S409 (2017).
Dhakal, S. & Klein, S. L. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J. Virol. 93, e00797–e00819 (2019).
Neidich, S. D. et al. Increased risk of influenza among vaccinated adults who are obese. Int. J. Obes. 41, 1324–1330 (2017).
Bustamante-Marin, X. M. et al. Mechanistic targets and nutritionally relevant intervention strategies to break obesity-breast cancer links. Front. Endocrinol. 12, 632284 (2021).
Shyer, J. A., Flavell, R. A. & Bailis, W. Metabolic signaling in T cells. Cell Res. 30, 649–659 (2020).
Soriano-Baguet, L. & Brenner, D. Metabolism and epigenetics at the heart of T cell function. Trends Immunol. 44, 231–244 (2023).
Chapman, N. M. & Chi, H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55, 14–30 (2022).
Boothby, M. & Rickert, R. C. Metabolic regulation of the immune humoral response. Immunity 46, 743–755 (2017).
Boothby, M. R., Brookens, S. K., Raybuck, A. L. & Cho, S. H. Supplying the trip to antibody production — nutrients, signaling, and the programming of cellular metabolism in the mature B lineage. Cell Mol. Immunol. 19, 352–369 (2022).
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A. & Sancho, D. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol. Immunol. 19, 384–408 (2022).
Sun, J. X., Xu, X. H. & Jin, L. Effects of metabolism on macrophage polarization under different disease backgrounds. Front. Immunol. 13, 880286 (2022).
Moller, S. H., Wang, L. & Ho, P. C. Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell Mol. Immunol. 19, 370–383 (2022).
MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259–283 (2013).
Kawai, T., Autieri, M. V. & Scalia, R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am. J. Physiol. Cell Physiol. 320, C375–C391 (2021).
Alwarawrah, Y. et al. Targeting T-cell oxidative metabolism to improve influenza survival in a mouse model of obesity. Int. J. Obes. 44, 2419–2429 (2020).
Rebeles, J. et al. Obesity-induced changes in T-cell metabolism are associated with impaired memory T-cell response to influenza and are not reversed with weight loss. J. Infect. Dis. 219, 1652–1661 (2019).
Green, W. D. et al. Metabolic and functional impairment of CD8+ T cells from the lungs of influenza-infected obese mice. J. Leukoc. Biol. 111, 147–159 (2022).
Endo, Y. et al. Obesity drives Th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 12, 1042–1055 (2015).
Pugh, G. H. et al. T cells dominate peripheral inflammation in a cross-sectional analysis of obesity-associated diabetes. Obesity 30, 1983–1994 (2022).
Batty, M. J., Chabrier, G., Sheridan, A. & Gage, M. C. Metabolic hormones modulate macrophage inflammatory responses. Cancers 13, 4661 (2021).
de Candia, P. et al. The pleiotropic roles of leptin in metabolism, immunity, and cancer. J. Exp. Med. 218, e20191593 (2021).
Kiernan, K. & MacIver, N. J. The role of the adipokine leptin in immune cell function in health and disease. Front. Immunol. 11, 622468 (2020).
Montague, C. T. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903–908 (1997).
Ozata, M., Ozdemir, I. C. & Licinio, J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84, 3686–3695 (1999).
Martin-Romero, C., Santos-Alvarez, J., Goberna, R. & Sanchez-Margalet, V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol. 199, 15–24 (2000).
Farooqi, I. S. et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110, 1093–1103 (2002).
Chandra, R. K. Cell-mediated immunity in genetically obese (C57BL/6J ob/ob) mice. Am. J. Clin. Nutr. 33, 13–16 (1980).
Mandel, M. A. & Mahmoud, A. A. Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J. Immunol. 120, 1375–1377 (1978).
Lam, Q. L., Wang, S., Ko, O. K., Kincade, P. W. & Lu, L. Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and cyclin D1. Proc. Natl Acad. Sci. USA 107, 13812–13817 (2010).
Frasca, D. & Blomberg, B. B. Adipose tissue inflammation induces B cell inflammation and decreases B cell function in aging. Front. Immunol. 8, 1003 (2017).
Deng, J. et al. The metabolic hormone leptin promotes the function of TFH cells and supports vaccine responses. Nat. Commun. 12, 3073 (2021).
Dudzinski, S. O. et al. Leptin augments antitumor immunity in obesity by repolarizing tumor-associated macrophages. J. Immunol. 207, 3122–3130 (2021).
Saucillo, D. C., Gerriets, V. A., Sheng, J., Rathmell, J. C. & Maciver, N. J. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J. Immunol. 192, 136–144 (2014).
Gerriets, V. A. et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur. J. Immunol. 46, 1970–1983 (2016).
Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).
Makhijani, P. et al. Regulation of the immune system by the insulin receptor in health and disease. Front. Endocrinol. 14, 1128622 (2023).
van Niekerk, G., Christowitz, C., Conradie, D. & Engelbrecht, A. M. Insulin as an immunomodulatory hormone. Cytokine Growth Factor. Rev. 52, 34–44 (2020).
Sun, Q., Li, J. & Gao, F. New insights into insulin: the anti-inflammatory effect and its clinical relevance. World J. Diabetes 5, 89–96, (2014).
Fischer, H. J. et al. The insulin receptor plays a critical role in T cell function and adaptive immunity. J. Immunol. 198, 1910–1920 (2017).
Tsai, S. et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 28, 922–934.e924 (2018).
Kiernan, K., Alwarawrah, Y., Nichols, A., Danzaki, K. & MacIver, N. J. Insulin and IGF-1 have both overlapping and distinct effects on CD4+ T cell mitochondria, metabolism, and function. Preprint at Res. Sq. https://doi.org/10.21203/rs.3.rs-3133824/v1 (2023).
Smith, W. J., Underwood, L. E. & Clemmons, D. R. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 80, 443–449 (1995).
Hawkes, C. P. & Grimberg, A. Insulin-like growth factor-I is a marker for the nutritional state. Pediatr. Endocrinol. Rev. 13, 499–511 (2015).
Clemmons, D. R. & Underwood, L. E. Nutritional regulation of IGF-I and IGF binding proteins. Annu. Rev. Nutr. 11, 393–412 (1991).
Lewitt, M. S., Dent, M. S. & Hall, K. The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus. J. Clin. Med. 3, 1561–1574 (2014).
DiToro, D. et al. Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity. Immunity 52, 650–667. e610 (2020).
Spadaro, O. et al. IGF1 shapes macrophage activation in response to immunometabolic challenge. Cell Rep. 19, 225–234 (2017).
Garcia-Estevez, L., Gonzalez-Martinez, S. & Moreno-Bueno, G. The leptin axis and its association with the adaptive immune system in breast cancer. Front. Immunol. 12, 784823 (2021).
Jimenez-Cortegana, C. et al. Leptin, both bad and good actor in cancer. Biomolecules 11, 913 (2021).
Harvey, A. E. et al. Calorie restriction decreases murine and human pancreatic tumor cell growth, nuclear factor-kappaB activation, and inflammation-related gene expression in an insulin-like growth factor-1-dependent manner. PLoS ONE 9, e94151 (2014).
de Gruil, N., Pijl, H., van der Burg, S. H. & Kroep, J. R. Short-term fasting synergizes with solid cancer therapy by boosting antitumor immunity. Cancers 14, 1390 (2022).
Lu, C. et al. Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. Int. Immunopharmacol. 77, 105969 (2019).
Helmstadter, J. et al. GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation. Antioxidants 10, 1175 (2021).
Shah, F. A. et al. Therapeutic effects of endogenous incretin hormones and exogenous incretin-based medications in sepsis. J. Clin. Endocrinol. Metab. 104, 5274–5284 (2019).
Insuela, D. B. R. & Carvalho, V. F. Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds. Eur. J. Pharmacol. 812, 64–72 (2017).
Steven, S. et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res. Cardiol. 110, 6 (2015).
Moschovaki Filippidou, F. et al. Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation. Am. J. Pathol. 190, 400–411 (2020).
Xue, S. et al. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann. N. Y. Acad. Sci. 1150, 152–156 (2008).
Itoh, A. et al. GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. J. Diabetes Complications 31, 1370–1375 (2017).
Chiou, H. C. et al. Dulaglutide modulates the development of tissue-infiltrating Th1/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system. Int. J. Mol. Sci. 20, 1584 (2019).
Xu, Q., Zhang, X., Li, T. & Shao, S. Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice. Mol. Med. 28, 144 (2022).
Pegtel, D. M. & Gould, S. J. Exosomes. Annu. Rev. Biochem. 88, 487–514 (2019).
Abels, E. R. & Breakefield, X. O. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol. Neurobiol. 36, 301–312 (2016).
Eguchi, A. et al. Microparticles release by adipocytes act as “find-me” signals to promote macrophage migration. PLoS ONE 10, e0123110 (2015).
Eguchi, A. et al. Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. J. Mol. Med. 94, 1241–1253 (2016).
Engin, A. Dark-side of exosomes. Adv. Exp. Med. Biol. 1275, 101–131 (2021).
Nakao, Y. et al. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine 36, 102430 (2021).
Deng, Z. B. et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 58, 2498–2505 (2009).
Kwan, H. Y., Chen, M., Xu, K. & Chen, B. The impact of obesity on adipocyte-derived extracellular vesicles. Cell Mol. Life Sci. 78, 7275–7288 (2021).
Kumar, V., Kiran, S., Kumar, S. & Singh, U. P. Extracellular vesicles in obesity and its associated inflammation. Int. Rev. Immunol. 41, 30–44 (2022).
Castano, C., Kalko, S., Novials, A. & Parrizas, M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc. Natl Acad. Sci. USA 115, 12158–12163 (2018).
Song, M. et al. Adipocyte-derived exosomes carrying sonic hedgehog mediate M1 macrophage polarization-induced insulin resistance via Ptch and PI3K pathways. Cell Physiol. Biochem. 48, 1416–1432 (2018).
Lei, L. M. et al. Exosomes and obesity-related insulin resistance. Front. Cell Dev. Biol. 9, 651996 (2021).
Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161–1172 (1996).
Lindenbergh, M. F. S. & Stoorvogel, W. Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu. Rev. Immunol. 36, 435–459 (2018).
Anel, A., Gallego-Lleyda, A., de Miguel, D., Naval, J. & Martinez-Lostao, L. Role of exosomes in the regulation of t-cell mediated immune responses and in autoimmune disease. Cells 8, 154 (2019).
Burrello, J. et al. Stem cell-derived extracellular vesicles and immune-modulation. Front. Cell Dev. Biol. 4, 83 (2016).
Qian, X. et al. Immunosuppressive effects of mesenchymal stem cells-derived exosomes. Stem Cell Rev. Rep. 17, 411–427 (2021).
Hade, M. D., Suire, C. N., Mossell, J. & Suo, Z. Extracellular vesicles: emerging frontiers in wound healing. Med. Res. Rev. 42, 2102–2125 (2022).
Sagini, K., Costanzi, E., Emiliani, C., Buratta, S. & Urbanelli, L. Extracellular vesicles as conveyors of membrane-derived bioactive lipids in immune system. Int. J. Mol. Sci. 19, 1227 (2018).
Pan, Y. et al. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. J. Clin. Invest. 129, 834–849 (2019).
Ying, W. et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171, 372–384.e312 (2017).
Ying, W. et al. MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in obese mice. Cell Metab. 33, 781–790.e785 (2021).
Purvinsh, L., Gorshkov, A., Brodskaia, A. & Vasin, A. Extracellular vesicles in viral pathogenesis: a case of Dr. Jekyll and Mr. Hyde. Life 11, 45 (2021).
Hulme, K. D., Noye, E. C., Short, K. R. & Labzin, L. I. Dysregulated inflammation during obesity: driving disease severity in influenza virus and SARS-CoV-2 infections. Front. Immunol. 12, 770066 (2021).
Wu, Q. et al. Cancer-associated adipocytes: key players in breast cancer progression. J. Hematol. Oncol. 12, 95 (2019).
Clement, E. et al. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020).
Dionisi, M. et al. Tumor-derived microvesicles enhance cross-processing ability of clinical grade dendritic cells. Front. Immunol. 9, 2481 (2018).
Marar, C., Starich, B. & Wirtz, D. Extracellular vesicles in immunomodulation and tumor progression. Nat. Immunol. 22, 560–570 (2021).
Zakeri, Z. et al. MicroRNA and exosome: key players in rheumatoid arthritis. J. Cell Biochem. 120, 10930–10944 (2019).
SantaCruz-Calvo, S. et al. Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities. Nat. Rev. Endocrinol. 18, 23–42 (2022).
Li, P. et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 21, 239–247 (2015).
Frasca, D., Romero, M., Garcia, D., Diaz, A. & Blomberg, B. B. Obesity accelerates age-associated defects in human B cells through a metabolic reprogramming induced by the fatty acid palmitate. Front. Aging 2, 828697 (2021).
Niraula, A. et al. Prostaglandin PGE2 receptor EP4 regulates microglial phagocytosis and increases susceptibility to diet-induced obesity. Diabetes 72, 233–244 (2023).
Schwarz, B. et al. Contribution of lipid mediators in divergent outcomes following acute bacterial and viral lung infections in the obese host. J. Immunol. 209, 1323–1334 (2022).
Virk, R. et al. Obesity reprograms the pulmonary polyunsaturated fatty acid-derived lipidome, transcriptome, and gene-oxylipin networks. J. Lipid Res. 63, 100267 (2022).
Mathews, J. A. et al. IL-33 drives augmented responses to ozone in obese mice. Environ. Health Perspect. 125, 246–253 (2017).
Neuhofer, A. et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 62, 1945–1956 (2013).
Crouch, M. J. et al. Frontline science: a reduction in DHA-derived mediators in male obesity contributes toward defects in select B cell subsets and circulating antibody. J. Leukoc. Biol. 106, 241–257 (2019).
Lopez-Vicario, C. et al. Leukocytes from obese individuals exhibit an impaired SPM signature. FASEB J. 33, 7072–7083 (2019).
Green, W. D. et al. Inflammation and metabolism of influenza-stimulated peripheral blood mononuclear cells from adults with obesity following bariatric surgery. J. Infect. Dis. 227, 92–102 (2022).
Fisk, H. L. et al. Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial. EBioMedicine 77, 103909 (2022).
Ramon, S. et al. The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? J. Immunol. 193, 6031–6040 (2014).
Kahnt, A. S., Schebb, N. H. & Steinhilber, D. Formation of lipoxins and resolvins in human leukocytes. Prostaglandins Other Lipid Mediat. 166, 106726 (2023).
Shu, T. et al. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA. Eur. Respir. J. 61, 2200582 (2023).
Serhan, C. N. & Levy, B. D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J. Clin. Invest. 128, 2657–2669 (2018).
Miao, T. et al. Decreased plasma maresin 1 concentration is associated with diabetic foot ulcer. Mediators Inflamm. 2020, 4539035 (2020).
Sugimoto, S. et al. Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation. Nat. Metab. 4, 775–790 (2022).
Schebb, N. H. et al. Formation, signaling and occurrence of specialized pro-resolving lipid mediators-what is the evidence so far? Front. Pharmacol. 13, 838782 (2022).
Al-Shaer, A. E. et al. Enriched marine oil supplement increases specific plasma specialized pro-resolving mediators in adults with obesity. J. Nutr. 152, 1783–1791 (2022).
Leiria, L. O. et al. 12-Lipoxygenase regulates cold adaptation and glucose metabolism by producing the omega-3 lipid 12-HEPE from brown fat. Cell Metab. 30, 768–783.e767 (2019).
Pal, A. et al. Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. FASEB J. 34, 10640–10656 (2020).
Zhang, N. et al. FFAR4 regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome. J. Lipid Res. 64, 100374 (2023).
Endo, J. et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J. Exp. Med. 211, 1673–1687 (2014).
Shaikh, S. R., Virk, R. & Van Dyke, T. E. Potential mechanisms by which hydroxyeicosapentaenoic acids regulate glucose homeostasis in obesity. Adv. Nutr. 13, 2316–2328 (2022).
Onodera, T. et al. Eicosapentaenoic acid and 5-HEPE enhance macrophage-mediated Treg induction in mice. Sci. Rep. 7, 4560 (2017).
Yamada, H. et al. 8-Hydroxyeicosapentaenoic acid decreases plasma and hepatic triglycerides via activation of peroxisome proliferator-activated receptor alpha in high-fat diet-induced obese mice. J. Lipids 2016, 7498508 (2016).
Liu, J. et al. The omega-3 hydroxy fatty acid 7(S)-HDHA is a high-affinity PPARalpha ligand that regulates brain neuronal morphology. Sci. Signal. 15, eabo1857 (2022).
de Bus, I., Witkamp, R., Zuilhof, H., Albada, B. & Balvers, M. The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation. Prostaglandins Other Lipid Mediat. 144, 106351 (2019).
Fisk, H. L. et al. Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids. Clin. Sci. 135, 185–200 (2021).
Monk, J. M. et al. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS ONE 7, e49739 (2012).
Borja-Magno, A. I. et al. Supplementation with EPA and DHA omega-3 fatty acids improves peripheral immune cell mitochondrial dysfunction and inflammation in subjects with obesity. J. Nutr. Biochem. 120, 109415 (2023).
Zeyda, M. et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J. Biol. Chem. 280, 14293–14301 (2005).
Rockett, B. D. et al. Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function. J. Lipid Res. 53, 674–685 (2012).
Hou, T. Y. et al. n-3 polyunsaturated fatty acids suppress CD4+ T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization. Biochim. Biophys. Acta 1858, 85–96 (2016).
Wang, X., Ilarraza, R., Tancowny, B. P., Alam, S. B. & Kulka, M. Disrupted lipid raft shuttling of FcepsilonRI by n-3 polyunsaturated fatty acid is associated with ligation of g protein-coupled receptor 120 (GPR120) in human mast cell line LAD2. Front. Nutr. 7, 597809 (2020).
Pettersson, U. S., Walden, T. B., Carlsson, P. O., Jansson, L. & Phillipson, M. Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. PLoS ONE 7, e46057 (2012).
Pauls, S. D. et al. Impact of age, menopause, and obesity on oxylipins linked to vascular health. Arterioscler. Thromb. Vasc. Biol. 41, 883–897 (2021).
Yaeger, M. J. et al. Sex differences in pulmonary eicosanoids and specialized pro-resolving mediators in response to ozone exposure. Toxicol. Sci. 183, 170–183 (2021).
Rabiee, M., Marjani, A., Khajeniazi, S. & Mojerloo, M. Genetic polymorphisms of cytochrome p450 (2C9) enzyme in patients with type 2 diabetes mellitus in Turkmen and Fars ethnic groups. Endocr. Metab. Immune Disord. Drug. Targets 18, 653–661 (2018).
Churchill, G. A., Gatti, D. M., Munger, S. C. & Svenson, K. L. The diversity outbred mouse population. Mamm. Genome 23, 713–718 (2012).
Lee, B. Y. et al. Research gaps and opportunities in precision nutrition: an NIH workshop report. Am. J. Clin. Nutr. 116, 1877–1900 (2022).
Acknowledgements
The authors would like to acknowledge the support of NIH grant P30DK056350 (S.R.S.); NIH grant R01ES031378 (S.R.S.); and NIH grant R21CA253163 (N.J.M.).
Author information
Authors and Affiliations
Contributions
M.A.B., S.R.S. and N.J.M. researched data for the article, contributed substantially to discussion of the content, wrote the article and reviewed and/or edited the manuscript before submission. Y.A. contributed substantially to discussion of the content and wrote the article.
Corresponding authors
Ethics declarations
Competing interests
S.R.S. has received industry support from Wiley Companies and Metagenics for studies on n-3 and n-7 fatty acids and from Sanofi, Solutex and Wiley Companies for organizing conferences. N.J.M., Y.A. and M.A.B. declare no competing interests.
Peer review
Peer review information
Nature Reviews Endocrinology thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Shaikh, S.R., Beck, M.A., Alwarawrah, Y. et al. Emerging mechanisms of obesity-associated immune dysfunction. Nat Rev Endocrinol 20, 136–148 (2024). https://doi.org/10.1038/s41574-023-00932-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-023-00932-2
- Springer Nature Limited
This article is cited by
-
Glucose restriction in antiviral defence
Nature Immunology (2024)
-
Diabetes and obesity: the role of stress in the development of cancer
Endocrine (2024)